Leerink analyst Andrew Berens downgraded Compass Therapeutics (CMPX) to Market Perform from Outperform with a price target of $4, down from $5. The firm sees a “number of uncertainties in key value drivers for the company.” The analyst removed the third-line colorectal cancer monotherapy and gastric cancer opportunities for CTX-009 due to lack of commitment to these settings.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics Reports Q3 2024 Financials and Clinical Progress
- Compass Therapeutics price target raised to $7 from $5 at Ladenburg
- Compass Therapeutics reports Q3 EPS (8c), consensus (11c)
- Compass Therapeutics sees cash runway into 1Q27
- Compass Therapeutics presents biomarker data related to CTX-471